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ABSTRACT
Objective: To determine the inciden’ce of low birth weight infants born to HIV seropositive women
and to demonstrate any effects of antiretroviral therapy on birth weight.
Methods: Retrospective review of all obstetrical medical records from January 1, 1995 through
June 30, 1998 to identify HIV seropositive women. We evaluated their antiretroviral therapy, CD4
counts, and birth weights of their newborns. We conducted detailed review of the clinical and
laboratory findings for the HIV-infected untreated patients, women who receivedZDV antepartum
alone, and those who received PIs as part of antiretroviral treatment.
Results: The frequency of low birth weight infants was significantly increased in HIV seropos-
itive compared to HIV seronegative parturients. Low birth weight infants were more frequent
among HIV infected women with lower CD4 counts but the association was not statistically
significant. Women who received no antepartum treatment, antepartum only ZDV, and those
treated with PIs had significantly more low birth weight infants than did comparison groups. HIV
seropositive women also had high frequencies of several obstetrical risk factors for low birth weight
infants.
Conclusion: The present study showed a significantly increased frequency of low birth weight
infants among HIV infected women and especially the subgroups of infected women who received
no antepartum treatment, antepartum ZDV only, and those treated with PIs. This association,
however, may be related to the presence ofmany other preterm obstetrical risk factors noted in this
study. Increasing numbers ofHIV seropositive women are being treated with PIs according to the
Centers for Disease Control (CDC) guidelines. If PIs are a cause of low birth weight infants,
women taking these drugs may have incremental risk of low birth weight. Infect. Dis. Obstet.
Gynecol. 8:94-98; 2000. (C) 2000 Wiley-Liss, Inc.
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he Pediatric AIDS Clinical Trials Group
(ACTG) protocol 076 study demonstrated a
very significant reduction in vertical transmission
of human immunodeficiency virus (HIV) with the
use of zidovudine (ZDV) monotherapy (25.5% to
8.3%). The study group of women was treated
antepartum and intrapartum, and the neonates
were also treated after birth. Despite this remark-
able result of perinatal pharmacotherapy on vertical
transmission of HIV in pregnancy, many questions
remain. One such question concerns the possible
adverse effects of the antiretroviral drugs to moth-
ers and infants. The U.S. Public Health Service
Task Force currently recommends combination
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therapy including the use of protease inhibitors
(Pls) in pregnant women, e However, at the
Twelfth World Congress on AIDS in Geneva,
1998, Lorenzi reported that Pls may contribute to
premature birth." This resulted in a temporary
moratorium on the use of Pls in ACTG clinical
trials involving pregnant women.4 Since low birth
weight is the major source of newborn morbidity
and mortality, and since premature birth is thought
to be a risk factor for perinatal transmission,s-ll
identifying an association with HIV therapy is criti-
cally important. We reviewed the Washington Hos-
pital Center experience with HIV seropositive
pregnant women to determine the frequency of
low birth weight in various cohorts; those patients
who were untreated and those who were treated
with various antiretroviral drugs.
MATERIALS AND METHODS
Medical records from all obstetrical patients from
January 1, 1995 through June 30, 1998 were re-
viewed to identify individuals who had confirmed
positive serological tests for HIV and recorded
birth weights of all infants. Clinical and laboratory
data were reviewed for patients who received no
treatment, those who received intrapartum ZDV
only, ZDV antepartum only, patients who received
combination therapy, patients who received both
antepartum and intrapartum ZDV, and patients
who received Pls as part of combination therapy.
Statistical tests included, where appropriate, the
Chi-square test and the two-tailed Fisher’s exact
test.
RESULTS
From January 1, 1995 through June 30, 1998,
10,635 infants were born at the Washington Hos-
pital Center. A total of 1809 low birth weight in-
fants (2500 gm), including 368 infants less than 500
gm, were born alive during this period. When the
less than 500 gm infants are excluded, the true
number of low birth weight infants is 1441. A total
of 107 infants were identified as being born to HIV
seropositive women, of whom 29 infants were low
birth weight by the above criteria (Table 1). The
frequency of low birth weight infants was signifi-
cantly increased in the HIV seropositive women
(29 of 107) (27.1%) compared to the HIV seroneg-
ative women (1412 of 10,160)(13.9%) (P -<0.001).
CD4 counts were available for 72 patients
within 2 months prior to delivery. Thirteen women
TABLE I. Antiretroviral therapy, type, and low birth
weight infants
Antiretroviral Number of
therapy patients
Low birth
weight
infants
(%)
No treatment 9 4 (44.4)
Intrapartum only
ZDV 13 6 (46. I)
Antepartum only
ZDV 9 5 (55.5)
ZDV + HIVIGIIVIG 0 (0)
ZDV + PI (I00)
Subtotal II 6 (54.5)
Antepartum + intrapartum
ZDV (A + I) 51 8 (I 5.7)
ZDV (A + I) + NVW (I) 0 (0)
ZDV (A + I) + HIVIG/IVIG (A) 8 0 (0)
ZDV (A + I) + 3TC (A) 6 2 (33.3)
ZDV (A + I) + 3TC (A) + NVP (I) 2 1(50)
ZDV (A + I) + 3TC (A) + D4T (A) 0 (0)
ZDV (A + I) + 3TC (A) + PI (A) 3 2 (66.6)
ZDV (A) + NVP (I) 2 0 (0)
Subtotal 74 13 (I 7.6)
TOTAL 107 29 (27. I)
aZDV Zidovudine.
bHIVIG/IVIG High titer HIVIV immunoglobulin or IV immunoglobulin.
cPI Protease inhibitor.
dA Antepartum; Intrapartum.
eNVP Nevirapine.
f3TC Lamivudine.
gD4T Stavudine.
had CD4 counts of 200 or less, and 5 delivered low
birth weight infants (38%). Thirty-five women had
CD4 counts between 200 to 500 and 9 delivered
low birth weight infants (26%). Twenty-five
women had CD4 counts of 500 or greater and only
3 had low birth weight infants (12%). These data
suggest a stepwise association between lower CD4
levels and increased rates of low birth weight in-
fants; however, statistical significance was not
achieved.
The effect of antiretroviral treatment on birth
weight was determined for several subgroups
(Table 2). The patients who received no treatment
were combined with those that were treated intra-
partum only since it is unlikely that therapy intra-
partum has an effect on birth weight (Group A).
The patients, who were treated antepartum only
were combined with those treated antepartum +
intrapartum because antepartum therapy poten-
tially has an effect on birth weight (Group B). The
frequency of low birth weight infants was signifi-
cantly higher among Group A women (no antepar-
tum antiretroviral treatment) (45.4%) compared to
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 95HIV IN PREGNANCYAND ANTIRETROVIRAL THERAPY GOLDSTEIN ET AL.
TABLE 2. Antiretroviral treatment subgroupsmtime
treated in pregnancy and low birth weight infants
Number of
Treatment subgroups patients
Low birth
weight
infants
(-<2500 gm)
A. No treatment and
intrapartum only treatment 22
B. All treatments, antepartum
and antepartum +
intrapartum 85
C. Protease inhibitors along
with other treatments,
antepartum and antepartum
+ intrapartum 4
D. No protease inhibitors. All
other treatments antepartum
and antepartum +
intrapartum 81
10 (45.4%)
19 (22.3%)
3 (75%)
16 (I 9.7%)
Group B women (antepartum antiretroviral treat-
ment (22.3%) (P 0.03).
For the Group A women we compared those
who had infants weighing -<2500 gm with those
who had infants weighing >2500 gm (Table 3). A
high frequency of obstetrical risk factors was ob-
served, and these were particularly increased in the
low-birth-weight weight group. The frequency of
preterm infants, prolonged rupture of membranes,
and infrequent prenatal care was higher in the
-<2500-gm infants. Cocaine abuse, HIV first diag-
nosed during intrapartum hospital stay, advanced
stage of AIDS (C3), and fetal death in utero were
similar for the two birth weight groups. Viral load
and CD4 determinations were too infrequent to
assess.
We noted that the women who received ante-
partum only ZDV monotherapy had a high fre-
quency of low birth weight infants (55.5%) (Table
1). We compared the patients who had infants
weighing -<2500 gm with those who had infants
weighing >2500 gm (Table 4). Four of the 5 low
birth weight infants were also preterm. Three of
these 5 women had each previously delivered at
least 2 other preterm babies. These 3 also had mul-
tiple sexually transmitted diseases. An additional
one of these patients delivered a dead fetus sec-
ondary to abruptio placenta at 31 weeks gestation.
The frequency of precipitous deliveries, prolonged
rupture of membranes, infrequent prenatal care,
cocaine abuse, HIV first identified during labor,
and advanced AIDS were similar for the two birth
weight groups.
TABLE 3. No antepartum treatment (Group A);
obstetrical risk factors for two birth weight groups
Birth weight Birth weight
-<2500 gm >2500 gm
Number of patients 10
Preterm (<-36 weeks gestation) 10
Premature rupture of membranes 6
Prolonged rupture of membranes 6
Infrequent prenatal care (<-2 visits) 9
Cocaine abuse 5
HIV first diagnosed intrapartum 3
Advanced aids (C3) 2
Fetal death in utero 0
12
2
NA
2
3
7
0
TABLE 4. Antepartum only ZDV; obstetrical risk
factors for two birth weight groups
Birth weight Birth weight
-<2500 gm >2500 gm
Number of patients 5 4
Preterm (<-36 weeks gestation) 4 0
Premature rupture of
membranes NA
Prior preterm deliveries 3 0
STDS ->2 during pregnancy 3 0
Fetal death in utero 0
Precipitous deliveries 4 3
Prolonged rupture of
membranes (->24 hours) 0 0
Infrequent prenatal care
(<-2 visits)
Cocaine abuse 2
HIV first identified intrapartum 0 0
Advanced AIDS (C3) 0 0
PIs were given along with other antiretroviral
drugs in the antepartum and antepartum + Intra-
partum category to four patients (Table 2, Group
C). Three of these 4 patients delivered low birth
weight infants who were also preterm. Other anti-
viral treatments without PIs were given antepar-
turn and antepartum + intrapartum to 81 women of
which 16 delivered low birth weight infants (Table
2, Group D). The frequency of low birth weight
infants was significantly higher in the PIs treated
Group C (75%) compared to the no PIs Group D
(19.7%) (P 0.033).
Table 5 demonstrates the clinical and laboratory
findings for the 4 patients in group C who were
treated with PIs. The 3 patients who had low birth
weight infants had several obstetrical risk factors
associated with low birth weight and preterm birth
including prolonged premature rupture of mem-
branes (2 patients), advanced AIDS CDC category
3 (2 patients), chorioamnionitis (2 patients), oligo-
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TABLE 5. Antiretroviral chemotherapy including protease inhibitors (Group C); clinical and laboratory findings
Birth weight <-2500 gm
Birth weight
>2500 gm
Patient Patient 2 Patient 3 Patient 4
Birth weight
Weeks gestation
Length of rupture of
membranes
CDC staging
Prenatal complications
Behavioral history
CD4 count
Viral load
1400 gm 810 gm 780 gm 3630 gm
31 6/7 27 4/7 26 4/7 40
4 d 0 hr 4 d 3 hr
C3 C3 AI A2
Premature ROM Oligohydramnios Premature ROM None
Chorioamnionitis Severe IUGR and PIH Chorioamnionitis
Tobacco, IV heroin, ETOH None Tobacco, cocaine, ETOH Tobacco
1/20 wks I/6 wks 16 I/8 wks 546 (PI start) I/I 2 wks 396
2/22 wks 6 (PI start) 2/19 wks 583
3/27 wks 28 3/25 wks 570
1/20 wks 49756 I/6 wks 360544 I/8 wks <400 (PI start) Not done
2/22 wks 49759 2/24 wks 3131 2/19 wks <400
(PI start) (2 wks post PI start)
3/27 wks 521 3/25 wks <400
hydramnios (1 patient), and cocaine or heroin
abuse (2 patients). Two of these 3 patients showed
significant decreases in viral load after the intro-
duction of Pls. These patients, however, did not
show significant increases in CD4 counts. One pa-
tient had undetectable viral load throughout the
period of study and similar data was not available
for the fourth and only full term patient.
DISCUSSION
Preterm birth is responsible for 70% of all fetal and
neonatal deaths in the United States. 12 Our expe-
rience at the Washington Hospital Center sug-
gested that there was a high rate of low birth
weight, preterm births among HIV seropositive
women. We therefore examined the potential as-
sociation between low birth weight and HIV sero-
positive parturients. We found that the frequency
of low birth weight infants among the HIV group
was significantly greater than the rate of low birth
weight infants among uninfected women.
We investigated CD4 levels to determine an as-
sociation with the increased rate of low birth
weight infants in our HIV seropositive patients. A
stepwise association between lower CD4 levels and
increased rates of low birth weight infants was
noted, however, this association did not achieve
statistical significance. We then studied the asso-
ciation of antepartum therapy on birth weight and
found that the women who had no antepartum an-
tiretroviral therapy had a statistically significant in-
crease in low birth weight infants, compared to
treated patients. Untreated women, however, also
had obstetrical factors that are associated with low
birth weight, including an increased frequency of
preterm infants, preterm rupture of membranes,
and infrequent prenatal care.
Next we analyzed women who received ante-
partum only ZDV since they also seemed to have a
high rate of low birth weight infants. Most of these
women also had many of the obstetrical factors that
are associated with low birth weight and preterm
infants. Incidentally, 4 of 22 women who received
no antepartum therapy were diagnosed as HIV se-
ropositive while hospitalized for preterm labor or
premature ruptured membranes.
We evaluated our patients who received Pls as
part of their therapy, and found that their preterm
birth rate was 75%, (3 of 4) which was significantly
higher compared with other treated patients.
These women, however, also had a high frequency
of obstetrical risk factors for low birth weight, pre-
term birth including prolonged, premature rupture
of membranes, advanced AIDS, chorioamnionitis,
oligohydramnios, and cocaine and heroin abuse. It
should be noted that at the time of the study, Pls
were generally reserved for patients with more ad-
vanced HIV disease.
A cause and effect relationship between Pls and
low birth weight, as first suggested by Lorenzi, "3 is
speculative. However, these drugs are known to
have many metabolic side effects including neph-
rolithiasis, hyperlipemia, hepatic metabolic alter-
ations, and glucose intolerance. 13 For example,
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both nelfinavir and ritonavir decrease the plasma
concentration of exogenously administered ethi-
nylestradiol. 14,1s The mechanism seems to be by
the PI induction of the hepatic P450 cytochrome
enzyme system. We would offer a hypothesis that
perturbations in the pregnancy milieu caused by
the effect of Pls on estrogen and/or progesterone
metabolism by Pls could lead to preterm labor. 16
In conclusion, we found a significantly increased
rate of low birth weight infants in our HIV sero-
positive patients, especially among those women
who did not receive antepartum antiretroviral treat-
ment and women who had antepartum only ZDV.
We also identified a significant association between
low birth weight and the use of Pls compatible
with the observation of Lorenzi et al. Women who
did not receive antepartum antiretroviral treat-
ment, women who received antepartum ZDV only,
and women who received Pls, also had a high fre-
quency of obstetrical risk factors, which may have
been responsible for the observed increased fre-
quency of low birth weight infants.
The concern about the use of PIs in pregnant
women based on Lorenzi’s data, was confirmed by
the present study. Because of the high rates of ob-
stetrical risk factors for low birth weight in the
pregnancies in HIV seropositive patient groups
studied, additional studies are needed to deter-
mine the possible role of obstetrical factors com-
pared to antiretroviral drugs including Pls in rela-
tion to low birth weight and preterm births.
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